Substance (Drug) Abuse is an indication for drug development with over 290 pipeline drugs currently active. According to GlobalData, preregistered drugs for Substance (Drug) Abuse have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Substance (Drug) Abuse compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Substance (Drug) Abuse overview

Substance abuse refers to the problematic pattern of consuming drugs or alcohol leading to detrimental effects on an individual’s physical and mental health, social relationships, and overall well-being. It involves the persistent use of substances despite knowing their harmful consequences. This abuse can encompass a wide range of substances, including illegal drugs, prescription medications, alcohol, or other chemicals. Substance abuse often leads to addiction, characterized by a compulsive need to seek and use the substance, tolerance, withdrawal symptoms upon cessation, and an inability to control its consumption. Treatment approaches include behavioral therapies, support groups, medications, and comprehensive rehabilitation programs focusing on addressing the underlying causes, managing cravings, and facilitating recovery and sobriety.

For a complete picture of PTSR and LoA scores for drugs in Substance (Drug) Abuse, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.